Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term [Yahoo! Finance]
MaxCyte, Inc. (MXCT)
Company Research
Source: Yahoo! Finance
estimates that might leave shareholders a little shell-shocked. Revenue and earnings per share (EPS) forecasts were both revised downwards, with analysts seeing grey clouds on the horizon. Following the downgrade, the consensus from seven analysts covering MaxCyte is for revenues of US$35m in 2024, implying an uneasy 16% decline in sales compared to the last 12 months. Losses are supposed to balloon 33% to US$0.48 per share. Yet before this consensus update, the analysts had been forecasting revenues of US$40m and losses of US$0.43 per share in 2024. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase. View our latest analysis for MaxCyte The consensus price target was broadly unchanged at US$9.78, perhaps implicitly signalling that the weaker earnings outlook is not expected to have a long-term impact on the valuation. Another way we c
Show less
Read more
Impact Snapshot
Event Time:
MXCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MXCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MXCT alerts
High impacting MaxCyte, Inc. news events
Weekly update
A roundup of the hottest topics
MXCT
News
- MaxCyte, Inc. (NASDAQ: MXCT) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $11.00 price target on the stock.MarketBeat
- We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth [Yahoo! Finance]Yahoo! Finance
- MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024GlobeNewswire
- Kytopen announces appointment of industry executive Kevin Gutshall as Chief Commercial Officer [Yahoo! Finance]Yahoo! Finance
- MaxCyte signs strategic platform license with Be Biopharma [Seeking Alpha]Seeking Alpha
MXCT
Earnings
- 3/12/24 - Beat
MXCT
Sec Filings
- 5/1/24 - Form ARS
- 4/26/24 - Form DEF
- 3/28/24 - Form 4
- MXCT's page on the SEC website